BCHE and Alzheimer disease: Current therapeutic options for AD in clinical practice, such as cholinesterase inhibitors (ChEI) and N-Methyl-D-aspartic acid receptor antagonists, provide symptomatic relief but fail to halt or reverse disease progression and often cause side effects like gastrointestinal disturbances and cardiovascular issues [3].